VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1 Statistically significant reductions in Lp(a) and liver inflammation No effect on weight either as a monotherapy or as add-on to semaglutide VTX3232... Read more
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leukemia with... Read more
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory maintenance dosing study of VK2735,... Read more
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking... Read more
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients Revita procedure demonstrated excellent safety and tolerability to date, consistent with prior clinical studies Results validate pivotal study design and reinforce Revita’s potential to be the first therapy for post-GLP-1 weight maintenance Company... Read more
Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today NEW YORK / Sep 22, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies... Read more
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy KELOWNA, BC / ACCESS Newswire / September 19, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide ("FTS") rodent biodistribution study (the "Study"). The main goal of the Study was to determine whether... Read more
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension The safety and tolerability profile of Mounjaro was generally consistent with previous adult studies INDIANAPOLIS, Sept. 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to... Read more
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants losing 20% or more body weight1** Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors1 Oral semaglutide 25 mg is the first oral GLP-1 therapy submitted to the US Food... Read more
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss Numeric improvements in metabolic and lipid parameters including waist circumference, blood pressure, cholesterol, triglycerides and A1C, were observed across all treatment groups TARRYTOWN, N.Y., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,... Read more
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs. 11.0 lbs (5.3%) with oral semaglutide, a 73.6% relative improvement, in a key secondary endpoint The safety and tolerability of orforglipron were consistent with previous trials INDIANAPOLIS, Sept. 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today... Read more
The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study Orforglipron demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity INDIANAPOLIS, Sept. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating... Read more
Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits1 This approval is based on results from the SOUL clinical trial, where oral semaglutide (Rybelsus®) reduced cardiovascular death, heart attack and stroke by 14% versus placebo, when added to standard of care, in adults with type 2 diabetes at high cardiovascular risk1 In addition, new results from SOUL will be presented at one of the... Read more
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary. Over the past several weeks, multiple proprietary film platforms were evaluated at Vektor Pharma. One of these... Read more
Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss,1 suggesting the impact of continued lifestyle support from Omada SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after d... Read more
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical... Read more
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1 Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in all treated people, regardless of... Read more
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy. Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical problems, and pediatric patients (12-17 years)... Read more
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 22.9 lbs (10.5%) on the highest dose, with A1C reduced by an average of 1.8% INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)... Read more
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data release... Read more
U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity Company to host “Commercial Readiness for Acquired Hypothalamic Obesity,” event for investors and analysts on Wednesday, September 24, in Boston BOSTON, Aug. 20, 2025 (GLOBE NEWSWIRE)... Read more
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study) Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies) New insights into the role of inflammation in cardiovascular disease on mortality and major car... Read more
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific... Read more
KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the important study milestone known as last patent last visit ("LPLV") in Lexaria's Phase 1b glucagon-like peptide-1 ("GLP-1") study in Australia, GLP-1-H24-4 (the "Study"). "We are delighted that this important... Read more
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study. The single dose,... Read more
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet... Read more
Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date New real-world findings are consistent with prior two-year clinical data from studies conducted outside the United States, reinforcing Revita’s potential for long-term metabolic control ahead of pivotal REMAIN-1 readouts... Read more
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM-139 (semaglutide implant) preclinical feasibility data showed approximately 20% weight loss maintained longer than 6 months with a single implant, continuing to support the potential for annual dosing Based on these data, Vivani... Read more
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug... Read more
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesity Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25 Continued Progress with Amylin Program; IND Planned 4Q25 Strong Quarter-End Cash Position of $808 Million SAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development... Read more
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in all 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide, and liraglutide KELOWNA, BC / ACCESS... Read more
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product portfolio beyond the recently successful Phase 3 D-PLEX100, demonstrating versatility of the Company's proprietary drug delivery platforms in multiple major therapeutic areas. PETACH TIKVA, Israel, July... Read more
Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling toxicology program ongoing IND submission planned for 4Q2025; Clinical data expected in 1H2026 PRINCETON, N.J., July 15, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that... Read more
Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine... Read more
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational... Read more
Bagsværd, Denmark, 8 July 2025 – Novo Nordisk today announced the submission of an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy® (subcutaneous semaglutide 7.2 mg). This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity, as part of their journey towards better health. The... Read more
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CALIFORNIA / ACCESS Newswire / June 30,... Read more
Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from SKNY-1, a next-generation oral therapeutic under definitive agreement for acquisition. In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and... Read more
No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1 MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment... Read more
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously... Read more
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss... Read more
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide... Read more
During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body weight regain by 46% and completely prevented fat regain compared to placebo The enobosarm treated groups showed up to 93% greater fat loss and 100% lean mass preservation compared to the placebo group at the end of the... Read more
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24,... Read more
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates... Read more
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Ef... Read more
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the margin of error for daily weight measurement), compared to expected 5–6% weight regain (10–15 pounds) after stopping GLP-1 therapy Revita continued to demonstrate excellent tolerability profile compared to GLP-1 drugs;... Read more
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of... Read more
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a key secondary endpoint The safety profile of orforglipron was consistent with the established GLP-1 class INDIANAPOLIS, June 21, 2025 /PRNewswire/ -- Eli Lilly and Company... Read more
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo1 Safety and tolerability of the higher dose of Wegovy® (semaglutide... Read more
